Search

Displaying results 4431 - 4440 of 10000 in total
  1. Drug

    Bevantolol

    go.drugbank.com/drugs/DB01295
    Investigational

    Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.

  2. Drug

    Cadralazine

    go.drugbank.com/drugs/DB13452
    Experimental

    Categories: Arteriolar Smooth Muscle, Agents Acting On
  3. Drug

    Butylated hydroxytoluene

    go.drugbank.com/drugs/DB16863
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Glycocyamine

    go.drugbank.com/drugs/DB02751
    Experimental

    Synonyms: N-amidinoglycine, N-(aminoiminomethyl)glycineCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Gemopatrilat

    go.drugbank.com/drugs/DB20954
    Experimental

    Gemopatrilat is a small molecule drug. Gemopatrilat has a monoisotopic molecular weight of 378.16 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Trandolaprilat

    go.drugbank.com/drugs/DB14209
    Experimental

    The active metabolite of the prodrug Trandolapril.

    Categories: Agents Acting on the Renin-Angiotensin System
  7. Drug

    Thenoyltrifluoroacetone

    go.drugbank.com/drugs/DB04795
    Experimental

    Thenoyltrifluoroacetone is a chelating agent and inhibitor of cellular respiration.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Tolu balsam

    go.drugbank.com/drugs/DB11223
    Investigational

    Categories: Compounds used in a research, industrial, or household setting, Complex Mixtures
  9. Drug

    Atractylodes japonica root oil

    go.drugbank.com/drugs/DB11270
    ApprovedWithdrawn

    It is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation.

  10. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    mutations in the kinase domain of FGFR. … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.